TD Asset Management
NRIX icon

TD Asset Management’s Nurix Therapeutics NRIX Stock Holding History

TD Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Buy
190,344
+1,094
+0.6% +$18.6K ﹤0.01% 821
2026
Q1 		$2.93M Sell
189,250
-47,950
-20% -$795K ﹤0.01% 888
2025
Q4 		$4.5M Buy
+237,200
New +$3.41M ﹤0.01% 818
2025
Q3 		– Sell
-42,420
Closed -$483K – 1272
2025
Q2 		$483K Hold
42,420
– – ﹤0.01% 1134
2025
Q1 		$504K Buy
42,420
+3,186
+8% +$53.3K ﹤0.01% 1146
2024
Q4 		$739K Sell
39,234
-1,200
-3% -$27.5K ﹤0.01% 1141
2024
Q3 		$932K Buy
40,434
+12,000
+42% +$272K ﹤0.01% 1200
2024
Q2 		$593K Buy
+28,434
New +$443K ﹤0.01% 1248
2023
Q1 		– Sell
-43,259
Closed -$475K – 1455
2022
Q4 		$475K Hold
43,259
– – ﹤0.01% 1295
2022
Q3 		$558K Hold
43,259
– – ﹤0.01% 1277
2022
Q2 		$548K Sell
43,259
-19,872
-31% -$225K ﹤0.01% 1275
2022
Q1 		$884K Sell
63,131
-26,606
-30% -$472K ﹤0.01% 1252
2021
Q4 		$2.6M Buy
89,737
+20,775
+30% +$630K ﹤0.01% 1072
2021
Q3 		$2.07M Hold
68,962
– – ﹤0.01% 1074
2021
Q2 		$2.12M Buy
68,962
+620
+0.9% +$18.2K ﹤0.01% 1074
2021
Q1 		$2.13M Buy
68,342
+30,398
+80% +$1.15M ﹤0.01% 1087
2020
Q4 		$1.25M Hold
37,944
– – ﹤0.01% 1133
2020
Q3 		$1.32M Buy
+37,944
New +$956K ﹤0.01% 1021

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management's NRIX Position: Q2 2026 in Review

TD Asset Management increased its Nurix Therapeutics (NRIX) stake by 0.58% in Q2 2026, buying an estimated $18.6K and bringing the position to 190,344 shares worth $4.62M. The position accounts for ﹤0.01% of the portfolio, ranked #821.

TD Asset Management first reported a position in NRIX in Q3 2020 and has held it in 18 quarters since. 135 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • TD Asset Management held 190,344 shares of Nurix Therapeutics worth $4.62M as of Q2 2026.
  • TD Asset Management bought 1,094 Nurix Therapeutics shares in Q2 2026, an estimated $18.6K.
  • Nurix Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #821 holding.
  • TD Asset Management first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 18 quarters since.
  • 135 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.